T
he relationship between obstructive sleep apnea (OSA) and cardiovascular disease is complex. Epidemiologic evidence indicates that OSA is an independent risk factor for cardiovascular morbidity. 1 The prevalence of hypertension is increased in subjects with OSA in a dose-dependent manner. [2] [3] [4] Similarly, the incidence of ischemic heart disease is increased with OSA, although the effect is more modest. 5 Conversely, OSA is more common in stable patients presenting with ischemic heart disease 6 and For editorial comment see page 4 acute myocardial infarction (MI). 7 More importantly, long-term outcomes following MI are worse in those who have OSA. 7, 8 For all of these reasons, making the diagnosis of OSA in patients with cardiovascular disease is important, particularly given that adequate management improves the control of BP, 9,10 the prognosis for patients with congestive cardiac failure, 11, 12 and the overall long-term mortality rate. 13 In the acute clinical setting, there is a dynamic interaction between sleep-disordered breathing (SDB) and cardiovascular function. Apneic events result in increased sympathetic nervous system activity, increased systemic BP, reduced myocardial oxygen delivery, and decreased cardiac output. 14 Even in healthy patients, ST-segment changes may be observed in association with prolonged apneas. 15 There is a strong relationship between SDB and left ventricular dysfunction, 16 probably because the hemodynamic consequences of obstructive apneas cause increased demand on the left ventricle. 14 Patients with left ventricular dysfunction are more at risk for serious ventricular arrhythmias, although evidence for life-threatening arrhythmias with OSA is rather scant. 17 On the other hand, left ventricular dysfunction is itself associated with abnormal breathing. Cheyne-Stokes respiration/central sleep apnea (CSA) occur in up to 40% of patients with congestive cardiac failure. 18 This adds further complexity to the interpretation of any abnormal breathing that may be observed in patients with unstable cardiovascular function.
Against this background, there is a need for increased awareness of sleep apnea in patients presenting with acute cardiovascular illness. The possibility of OSA as a treatable risk factor may not previously have been considered. Even where it has, facilities for the adequate investigation of OSA are often extremely limited. Discharging a patient from the hospital with acute cardiovascular illness without a definitive diagnosis will delay appropriate intervention, and so the possibility of confirming OSA promptly would be an advantage. Recently, a reliable portable monitoring device that is suitable for the diagnosis of SDB outside the sleep laboratory has become available. 19 Using this approach, we aimed to identify the frequency of OSA and other sleeprelated breathing disorders in consecutive patients who were admitted to a coronary care unit (CCU). We reasoned that this would provide the basis for improved overall care by identifying and treating an important risk factor in a high-risk group of patients.
Patients and Methods
Consecutive patients admitted to the Coronary Care Unit of Dunedin Hospital between April 1 and May 31, 2003, were invited to participate as soon as their clinical status had been satisfactorily stabilized. Inclusion criteria were as follows: diagnosis of unstable angina; acute MI; and left ventricular or congestive cardiac failure. Exclusion criteria were as follows: known diagnosis of OSA or other sleep-related disorder; or requiring ongoing supplementary oxygen therapy at the time of the proposed sleep study (this precluded airflow measurements using thermistors). All patients completed the Epworth sleepiness scale (ESS) questionnaire. 20 Height and weight were recorded.
Two overnight sleep studies were performed. The first was carried out in the CCU or in the adjacent cardiology ward using a portable diagnostic device (Embletta; Flaga Medical Devices; Reykjavik, Iceland). The device is suitable for use both in hospital and at home, and it has been validated against full polysomnography. 19 In that investigation, the apnea-hypopnea index (AHI) per hour in bed differed on average by a mean (Ϯ SD) of 3 Ϯ 9 events per hour from the AHI per hour in bed that was obtained from a synchronous full polysomnography, with an overall tendency for the underestimation of AHI using the portable diagnostic device. The parameters measured were as follows: nasal and oral airflow using two appropriately placed thermistors; thoracoabdominal movements via two piezoelectric bands; pulse oximetry using a finger probe; snoring episodes detected via a vibration sensor placed anterior to the sternomastoid muscle; and continuous actigraphy to monitor and record body position. In cases in which narcotic analgesics, sedatives, or hypnotic drugs had been used during the previous 12 h, the study was deferred until these were no longer required for at least 12 h. A second identical overnight study was performed in the patient's home at least 6 weeks after discharge from the hospital or, if necessary, at a later time when the patient's clinical status was deemed to be stable. This was to confirm the repeatability of the findings obtained during the hospital-based study.
Outputs from the portable diagnostic device were scored manually by two sleep laboratory technicians without knowledge of the clinical characteristics of the patient. Using the manually scored data, the AHI (events per hour) was computed using a computer program (Somnologica; Flaga Medical Devices). Apneas were defined as the complete cessation of airflow, and hypopneas were defined as a reduction in thoracoabdominal movement of Ͼ 50%, each for Ն 10 s. Central and obstructive apneas were distinguished by the presence or absence of thoracoabdominal movements during an apnea. The AHI was calculated as the number of respiratory events per hour of recording time in bed, with the start of recording being the point at which respiration settled to a rhythmic, stable pattern. The end of the recording time was either the waking time recorded by the subject or the point at which the thoracoabdominal tracings became disturbed, which was consistent with wakefulness. An AHI of Ն 15 events per hour was considered to be clinically significant. 21 The sleep habits, daytime sleepiness, activity, snore symptoms, general health, and medication use for the subject were recorded using standardized questionnaires including the following: the ESS 20 ; the functional outcomes of sleep questionnaire 22 ; the Medical Outcomes Study 36-item short form 23 ; and the Scottish Sleep Health Survey. 24 The questionnaires were administered at the time of enrollment into the study and were repeated in those subjects who underwent a second study.
The study was approved by the Otago Ethics Committee, and each patient gave written informed consent. At the end of the study, individual results were communicated to each patient and, where appropriate, treatment was offered.
Statistical Analysis
Descriptive statistics were obtained for each of the primary end points and are reported as group means with SDs or ranges. The t tests and 2 test were used where appropriate.
Results
There were 101 admissions to the CCU during the designated study period, of which 41 met the diagnostic criteria for inclusion in the study. Twelve patients declined to participate. Twenty-nine pa-tients underwent the first sleep study (study 1), but complete data were available for only 26 patients. The remaining three patients were either intolerant of monitoring procedures 2 or experienced chest pain during the study night. 1 The final CCU admission diagnosis was MI in 14 patients (complicated by left ventricular failure in 2 patients), unstable angina in 11 patients, and isolated left ventricular failure in only 1 patient. The second sleep study (study 2) was carried out in 18 patients (69%) after a mean interval of 74 Ϯ 5 days (range, 38 to 106 days). Of those eight patients who withdrew between the first and second studies, two patients were deceased, two were unwell with unrelated illnesses, and three declined to participate further, indicating that they had no problems with sleep. One subject was unavailable for follow-up.
The demographic details for the study population at entry are shown in Table 1 . Fifteen of the 26 patients (58%) had a history of hypertension. SDB (ie, AHI, Ն 15) was identified in 13 of 26 patients (50%) at the time of study 1. These figures were even greater using less rigorous criteria to define SDB (Table 2) . A diagnosis of OSA was made in 12 patients (46%). One patient had CSA. Following study 2, the diagnosis of SDB was confirmed in only 5 of 18 patients (28%); all 5 patients had OSA. Six of the 18 patients (33%) in whom SDB was diagnosed during study 1 were shown not to have SDB at study 2 (Table 3) . One patient with a negative result during study 1 received a diagnosis of SDB during study 2. Among those six patients who had a false-positive result in study 1, the mean percentage of time spent in the supine position fell significantly between the study 1 and study 2 (p ϭ 0.019). However, only three of these six patients met the formal criteria for a diagnosis of positional OSA during study 1. 25 Detailed sleep study data for the 18 patients who completed both studies are contained in Table 2 . In these 18 patients, the mean percentage of time spent in the supine position fell from 33.1 Ϯ 25.0% to 19.2 Ϯ 17.9% (difference not significant).
Clinical follow-up was arranged for all patients with SDB confirmed at study 2. Two patients received treatment with continuous positive airway pressure, and in the remainder it was recommended that continuous positive airway pressure should be commenced in the future either if the patient's cardiac status deteriorated, if hypertension became difficult to stabilize, or if daytime hypersomnolence developed.
An analysis of the results for ESS scores did not reveal any consistent relationship between the ESS score and the AHI. Only 4 of 26 patients (16%) with a diagnosis of SDB during study 1 had an ESS score of Ն 10. Outcomes from the other standardized questionnaires were unremarkable apart from the Medical Outcomes Study 36-item short form mental health scores that were obtained during study 2, which were consistent with the results obtained with MI. 23 
Discussion
The results of this observational study confirm that SDB is common in a highly selected group of at-risk patients who are admitted to the CCU. Using very conservative criteria for diagnosis, 12 patients (46%) were shown to have OSA and 1 had CSA at the time of their acute presentation. However, the results of the follow-up investigation showed that in a significant number of patients, the findings were transient and could not be repeated. A final diagnosis of SDB was confirmed in 5 of 26 patients (19% of the original study group). Using less stringent criteria (ie, AHI, Ն 5), these figures were significantly greater, as follows: 19 of 26 patients (73%) at baseline qualified for a diagnosis of SDB; and 15 of 18 patients (83%) on the repeat study night qualified for a diagnosis of SDB. Given the high prevalence of SDB using these latter thresholds, it is probably wiser to arrive at a diagnosis and to offer treatment based on the more rigorous criteria.
Our results have important practical implications. Identifying and treating risk factors that are known to influence long-term outcomes in patients with cardiovascular disease are important aspects of secondary prevention. Arguably, this should be done as early as possible when patients are in contact with clinical staff whose awareness of these risk factors is high and in a setting where facilities for prompt investigation are more likely to be available. How- ever, based on our findings, attempting to diagnose SDB early in patients with acute cardiovascular presentations should be approached with caution.
Our results indicate that casual observations made in the acute setting by clinical staff need not necessarily be indicative of an ongoing problem, and performing sleep studies shortly after admission to the CCU may be wasteful of very limited resources, given the high rate of false-positive diagnoses (6 of 18 diagnoses; 33%). There are a number of possible reasons for the high false-positive diagnosis rate (ie, patients with either a truly false-positive diagnosis or alternatively patients who have transient SDB for whatever reason). First, acute cardiovascular pathology may itself result in abnormal breathing during sleep, notably with a tendency to central apnea events. Overall, our results did not indicate a significant change in the frequency of central apneas (18 apneas), but in the group of patients who were deemed to have a false-positive diagnoses, the mean frequency of central apnea events fell from 12.5 Ϯ 21.0 to 1.2 Ϯ 2.3 events per hour (difference not significant). An alternative explanation is that patients are more likely to lie supine in the CCU setting compared to their own home because of the need for additional instrumentation (eg, ECG leads). In those subjects with a positive diagnosis at the time of study 1, the time spent in the supine position in the CCU study was significantly greater than that during the later domiciliary study (study 2) [ Table 3 ]. Certain drugs (eg, narcotic analgesics and hypnotic/anxiolytic agents) may affect breathing while asleep, and these are commonly used in the CCU. As far as possible, Table 2 for abbreviation not used in the text. 17,26 -28 In the report by Mooe et al, 17 37% of patients with severe angina pectoris had an AHI of Ն 5 events per hour. Earlier, Saito et al 27 reported that 100% of 49 patients with acute MI had apneas, and Hung et al 26 reported that 36% of male patients studied within 1 to 8 weeks following an MI had OSA. In these earlier studies, the exact timing of investigation in relation to cardiac events and/or coronary angiography was either not stated, 26 was variable, 28 or occurred within 6 days of hospital discharge. 27 Thus, the validity of the findings in these investigations is not known, and for reasons that are similar to our own study, it may be that either transient SDB or a false-positive diagnosis was being reported. The apparently high prevalence of SDB in each of these studies comprising patients with cardiovascular disease, including the present one, is higher than that in the "normal" population. 29 However, this may also be a function of age. Only nine of our patients were aged Ͻ 65 years, and it is known that in persons who are Ͼ 65 years of age the frequency of SDB ranges from 24 to 42%. 30, 31 In conclusion, SDB occurs commonly in patients presenting with an acute cardiovascular event, and considering the diagnosis of SDB in patients in this high-risk group is an important strategy for secondary prevention. However, our findings indicate that, when investigated in the short term, sleep-related breathing abnormalities are often transient. For this reason, sleep studies to investigate SDB as a potential risk factor for cardiovascular morbidity should be carried out when the patient is clinically stable.
